Malek B. Hannouf

463 citations

28 papers · 343 indexed · h-index 11

Otorhinolaryngology top 5%
- Head and Neck Cancer Studies 5
Radiation top 10%
Oncology
- Cancer Diagnosis and Treatment 7
- HER2/EGFR in Cancer Research 7
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 5
- Lung Cancer Diagnosis and Treatment 4
Cancer Research
- Breast Cancer Treatment Studies 8
Pathology and Forensic Medicine
- Tumors and Oncological Cases 4
Hepatology
- Hepatocellular Carcinoma Treatment and Prognosis 3

Co-authors: Gregory S. Zaric Muriel Brackstone Sunil Verma Nancy Nixon George Rodrigues David A. Palma Alexander V. Louie Joseph D. Mocanu
Cited by: Otorhinolaryngology Radiation Oncology
Journals: Journal of Clinical Oncology (4 papers)PLoS ONE (1 paper)International Journal of Radiation Oncology*Biology*Physics (3 papers)
Partner nations: Canada United States Netherlands

In The Last Decade

Malek B. Hannouf

27 papers receiving 337 citations

Peers

Countries citing papers authored by Malek B. Hannouf

Since Specialization

Citations

This map shows the geographic impact of Malek B. Hannouf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Malek B. Hannouf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Malek B. Hannouf more than expected).

Fields of papers citing papers by Malek B. Hannouf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Malek B. Hannouf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Malek B. Hannouf. The network helps show where Malek B. Hannouf may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Malek B. Hannouf, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Malek B. Hannouf Line = papers co-authored together Malek B. Hannouf links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review Cancers ·Danilo Giffoni de Mello Morais Mata,Rania Chehade,Malek B. Hannouf,Jacques Raphael,Phillip Blanchette,Abdullah Al-Humiqani,Monali Ray	2023	1
2	Cost-effectiveness analysis of a circulating tumor DNA-based molecular residual disease assay to guide adjuvant chemotherapy decisions in patients with resectable early stage colorectal cancer. Journal of Clinical Oncology ·John A. Schneider,Ryan Bresnahan,Nadine Chami,Muriel Brackstone,Malek B. Hannouf	2023	2
3	Developing a clinical-pathologic model to predict genomic risk of recurrence in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative, node negative breast cancer Cancer Treatment and Research Communications ·Atul Batra,Nancy Nixon,Gloria Roldan-Urgoiti,Malek B. Hannouf,Tasnima Abedin,Judith Hugh,Karen King,Gilbert Bigras,Tanner Steed,Sasha Lupichuk	2021	3
4	Cause-effect chains in S-LCA based on DPSIR framework using Markov healthcare model: an application to “working hours” in Canada The International Journal of Life Cycle Assessment ·Marwa Hannouf,Getachew Assefa,Malek B. Hannouf,Ian D. Gates	2021	16
5	Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study The Breast ·Atul Batra,Malek B. Hannouf,Noura Alsafar,Sasha Lupichuk	2020	5
6	Real-world Safety and Efficacy of Raltitrexed in Patients With Metastatic Colorectal Cancer Clinical Colorectal Cancer ·Atul Batra,Rodrigo Rigo,Malek B. Hannouf,Winson Y. Cheung	2020	10
7	Survival Outcome Differences Based on Treatments Used and Knowledge of the Primary Tumour Site for Patients with Cancer of Unknown and Known Primary in Ontario Current Oncology ·C.S. Kim,Malek B. Hannouf,Sisira Sarma,George Rodrigues,Peter K. Rogan,Salaheddin M. Mahmud,Eric Winquist,Muriel Brackstone,Gregory S. Zaric	2018	16
8	The Evolution of Biosimilars in Oncology, with a Focus on Trastuzumab Current Oncology ·Nancy Nixon,Malek B. Hannouf,Sunil Verma	2018	26
9	The Clinical Significance of Occult Gastrointestinal Primary Tumours in Metastatic Cancer: A Population Retrospective Cohort Study Cancer Research and Treatment ·Malek B. Hannouf,Eric Winquist,Salaheddin M. Mahmud,Muriel Brackstone,Sisira Sarma,George Rodrigues,Peter K. Rogan,Jeffrey S. Hoch,Gregory S. Zaric	2017	2
10	The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort Study PharmacoEconomics - Open ·Malek B. Hannouf,Eric Winquist,Salaheddin M. Mahmud,Muriel Brackstone,Sisira Sarma,George Rodrigues,Peter K. Rogan,Jeffrey S. Hoch,Gregory S. Zaric	2017	7
11	A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer European Journal of Cancer ·Nancy Nixon,Malek B. Hannouf,Sunil Verma	2017	27
12	Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary The Pharmacogenomics Journal ·Malek B. Hannouf,Eric Winquist,Salaheddin M. Mahmud,Muriel Brackstone,Sisira Sarma,George Rodrigues,Peter K. Rogan,Jeffrey S. Hoch,Gregory S. Zaric	2016	9
13	Identification and survival outcomes of a cohort of patients with cancer of unknown primary in Ontario, Canada Acta Oncologica ·Chong S. Kim,Malek B. Hannouf,Sisira Sarma,George Rodrigues,Peter K. Rogan,Salaheddin M. Mahmud,Eric Winquist,Muriel Brackstone,Gregory S. Zaric	2015	8
14	Cost Effectiveness of a 21-Gene Recurrence Score Assay Versus Canadian Clinical Practice in Post-Menopausal Women with Early-Stage Estrogen or Progesterone-Receptor-Positive, Axillary Lymph-Node Positive Breast Cancer PharmacoEconomics ·Malek B. Hannouf,Bin Xie,Muriel Brackstone,Gregory S. Zaric	2013	11
15	Identification of the occult tumor in cancer of unknown primary (CUP): A priority based on histology. Journal of Clinical Oncology ·Chong Sung Kim,Malek B. Hannouf,Muriel Brackstone,Eric Winquist,Gregory S. Zaric	2013	3
16	Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer BMC Cancer ·Malek B. Hannouf,Bin Xie,Muriel Brackstone,Gregory S. Zaric	2012	22
17	Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer PLoS ONE ·Malek B. Hannouf,Chander Sehgal,Jeffrey Cao,Joseph D. Mocanu,Eric Winquist,Gregory S. Zaric	2012	35
18	Evaluating the Efficacy of Current Clinical Practice of Adjuvant Chemotherapy in Postmenopausal Women with Early-Stage, Estrogen or Progesterone Receptor–Positive, One-To-Three Positive Axillary Lymph Node, Breast Cancer Current Oncology ·Malek B. Hannouf,Muriel Brackstone,Bin Xie,Gregory S. Zaric	2012	6
19	Withholding stereotactic radiotherapy in elderly patients with stage I non-small cell lung cancer and co-existing COPD is not justified: Outcomes of a markov model analysis Radiotherapy and Oncology ·Alexander V. Louie,George Rodrigues,Malek B. Hannouf,Frank J. Lagerwaard,David A. Palma,Gregory S. Zaric,Cornelis J.A. Haasbeek,Suresh Senan	2011	43
20	Stereotactic Body Radiotherapy Versus Surgery for Medically Operable Stage I Non–Small-Cell Lung Cancer: A Markov Model–Based Decision Analysis International Journal of Radiation OncologyBiologyPhysics ·Alexander V. Louie,George Rodrigues,Malek B. Hannouf,Gregory S. Zaric,David A. Palma,Jeffrey Cao,Brian Yaremko,Richard Malthaner,Joseph D. Mocanu	2010	53

About Malek B. Hannouf

Malek B. Hannouf is a scholar working on Otorhinolaryngology, Oncology and Cancer Research, having authored 28 papers that have together received 343 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (8 papers), Cancer Diagnosis and Treatment (7 papers), HER2/EGFR in Cancer Research (7 papers), Head and Neck Cancer Studies (5 papers), Lung Cancer Treatments and Mutations (5 papers), Tumors and Oncological Cases (4 papers), Lung Cancer Diagnosis and Treatment (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). The work is most often cited by research in Otorhinolaryngology (54 citations), Radiation (52 citations) and Oncology (135 citations). Malek B. Hannouf has collaborated with scholars based in Canada, United States and Netherlands. Frequent co-authors include Gregory S. Zaric, Muriel Brackstone, Sunil Verma, Nancy Nixon, George Rodrigues, David A. Palma, Alexander V. Louie, Joseph D. Mocanu, Jeffrey Cao and Eric Winquist. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and International Journal of Radiation Oncology*Biology*Physics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact